Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

Walmsley, Sharon; Antela, Antonio; Clumeck, Nathan; Duiculescu, Dan; Eberhard, Andrea; Gutiérrez, Félix; Hocqueloux, Laurent; Maggiolo, Franco; Sandkovsky, Uriel; Granier, Catherine; A. Pappa, Keith; Wynne, Brian; Min, Sherene; Nichols, Garrett

doi:10.1056/nejmoa1215541

Public

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

Published in New England Journal of Medicine • Nov 6, 2013

Authors:

Sharon Walmsley

Antonio Antela

Nathan Clumeck

Abstract

BACKGROUND: Dolutegravir (S/GSK1349572), a once-daily, unboosted integrase inhibitor, was recently approved in the United States for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in combination with other antiretroviral agents. Dolutegravir, in combination with abacavir-lami...

Subject

Dolutegravir

Abacavir

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!